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Cyclophosphamide Promotes Chronic
Inflammation–Dependent Immunosuppression and
Prevents Antitumor Response in Melanoma
Alexandra Sevko1,7, Moshe Sade-Feldman2,7, Julia Kanterman2,7, Tillmann Michels1, Christine S. Falk3,
Ludmila Umansky4, Marcel Ramacher1, Masashi Kato5, Dirk Schadendorf6, Michal Baniyash2 and
Viktor Umansky1
Low-dose cyclophosphamide (CP) therapy induces immunogenic tumor cell death and decreases regulatory
T cell (Treg) numbers in mice with transplantable tumors. Using the ret transgenic murine melanoma model that
resembles human melanoma, we detected no beneficial antitumor effects with such treatment, despite a
decrease in Tregs. On the contrary, low-dose CP enhanced the production of chronic inflammatory mediators in
melanoma lesions associated with increased accumulation of Gr1þCD11bþ myeloid-derived suppressor cells
(MDSCs), which exhibit elevated suppressive activity and nitric oxide (NO) production as well as inhibition of
T-cell proliferation. Moreover, the frequencies of CD8þ T cells in the tumors and their ability to produce perforin
were decreased. To study whether the observed CP-induced MDSC expansion and activation also occurs under
chronic inflammatory tumor-free conditions, mice exhibiting chronic inflammation were treated with CP. Similar
to tumor-bearing mice, CP-treated inflamed mice displayed elevated levels of MDSCs with enhanced production
of NO, reactive oxygen species, and a suppressed in vivo natural killer (NK) cell cytotoxic activity indicating CP
effects on the host immune system independent of the tumor. We suggest that melanoma therapy with low-dose
CP could be efficient only when combined with the neutralization of MDSC immunosuppressive function and
chronic inflammatory microenvironment.
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INTRODUCTION
Human malignant melanoma, known for its poor response to
therapeutics, is one of the fastest growing cancers (MacKie
et al., 2009). Chemotherapy belongs to the standard
melanoma treatment, although its efficacy is low. Moreover,
chemotherapeutics in maximum tolerated doses can induce
immunosuppression in tumor-bearing hosts (Gerber and
Steinberg, 1976; Athanasiadou et al., 2002; Weiner
and Cohen, 2002). In contrast, low-dose chemotherapy
stimulated antitumor immunity (Obeid et al., 2007; Zitvogel
et al., 2008). In particular, anthracyclins increased the tumor
cell immunogenicity by inducing immunogenic cell death
through efferocytosis (Obeid et al., 2007). In contrast to
classical apoptosis, which is considered as tolerogenic and
anti-inflammatory (Zitvogel et al., 2008), efferocytosis
mediated by calreticulin (CRT) and LRP/91/Rac-1 pathway
showed its immunostimulatory potential (Gardai et al., 2006).
Tumor progression is driven by chronic inflammation
developed in the tumor microenvironment and represented
by infiltrating leukocytes and soluble mediators (Baniyash,
2006; Gabrilovich and Nagaraj, 2009; Ostrand-Rosenberg and
Sinha, 2009; Rook and Dalgleish, 2011). These mediators
support tumor development by stimulating pro-tumor
mutations, resistance to apoptosis, and angiogenesis (Tan
and Coussens, 2007; Mantovani et al., 2008). Moreover,
some of these factors induce the expansion and activation of
immunosuppressive cells, such as myeloid-derived suppressor
cells (MDSCs) and M2 macrophages, in tumor lesions and in
the periphery (Baniyash, 2006; Serafini et al., 2006;
Gabrilovich and Nagaraj, 2009; Ostrand-Rosenberg, 2010).
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Cyclophosphamide (CP) at low doses has been recently
applied in melanoma treatment combined with various
immunotherapies (Koike et al., 2008; Quan et al., 2008). In
animal models, low-dose CP showed an antiangiogenic
activity by killing circulating endothelial progenitors
(Bertolini et al., 2003) and decreased nitric oxide (NO)
concentrations in serum (Loeffler et al., 2005). Moreover, CP
reduced numbers and suppressed the function of regulatory
T cells (Tregs) in tumor-bearing hosts (Lutsiak et al., 2005;
Motoyoshi et al., 2006). Furthermore, CP administration to
tumor-bearing mice not only stimulated the mobilization of
bone marrow (BM) dendritic cells (DCs) (Salem et al., 2009),
but also activated their antigen-processing machinery by
inducing pre-apoptotic surface translocation of CRT on
tumor cells (Obeid et al., 2007; Sistigu et al., 2011).
However, the CP effects on chronic inflammatory
environment that drives the tumor progression are poorly
investigated.
In this study, we used the ret transgenic mouse model that,
in contrast to transplantation models, shows similarity to
human melanoma (Kato et al., 1998; Umansky et al., 2008).
Tumor-bearing mice developed metastases in lymph nodes
(LNs), lungs, liver, brain, and BM (Umansky et al., 2008). This
metastatic profile resembles that of human melanoma
(Houghton and Polsky, 2002; Patnana et al., 2011). We
found that although low-dose CP induced pre-apoptotic
surface translocation of CRT on Ret melanoma cells in vitro
and decreased Treg numbers in transgenic tumor-bearing mice
in vivo, it could not delay the melanoma progression. CP
stimulated the production of chronic inflammatory mediators
associated with an elevation of MDSC frequencies and
immunosuppressive activity in melanoma lesions. Mice with
chronic inflammation induced by Bacillus Calmette–Gue´rin
(BCG) (Vaknin et al., 2008) displayed a similar enhancement
of MDSC frequencies and functions. Our data suggest that an
enhancement of antitumor T-cell reactivity because of Treg
depletion by low-dose CP can be efficiently blocked by
activated MDSCs induced by chronic inflammation
enhanced with CP treatment.
RESULTS
Low-dose CP induces immunogenic melanoma cell death leading
to increased DC maturation in vitro
Ret melanoma cells established from skin melanomas of ret
transgenic mice were treated in vitro with CP at low
concentrations (5 or 10 mM). Cytotoxic effects were estimated
by the staining with Annexin V and propidium iodide (PI)
(Figure 1). CP at both concentrations induced a significant
increase in the numbers of dead melanoma cells at day 2 after
treatment (Figure 1b). Analysis of immunogenic cell death
marker, CRT, revealed its appearance on some nonapoptotic
AnnexinV-PI- Ret cells (i.e., before phosphatidylserine translo-
cation) at day 2 of coincubation with 5 mM but not 10 mM CP
(Figure 1c). Moreover, these cells displayed a significantly
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Figure 1. Low-dose cyclophosphamide (CP) induces the calreticulin (CRT) expression on Ret melanoma cells. Tumor cells were treated with CP for 48 hours
followed by flow cytometry. (a) A representative dot plot of cells treated with 10 mM CP is shown. (b) Cumulative data for dead cells are expressed as the
percentage of apoptotic and necrotic cells (AnnexinVþPIþ ) among the total treated population. PI, propidium iodide. (c) Cumulative data for the surface CRT
expression on live cells (AnnVPI ) are shown as the percentage of CRTþ cells within total live cells. AnnV, Annexin V. (d) The level of CRT expression on live
cells is presented as mean fluorescence intensity (MFI). The results from b to d are representative of three independent experiments conducted in triplicate with
similar data. Error bars represent SE. *Po0.05.
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higher level of CRT expression (Figure 1d). Therefore, an
increase in CRT expression on melanoma cells upon coculture
with CP was detected before the beginning of apoptosis,
suggesting an induction of immunogenic cell death.
To test directly the increased immunogenicity of Ret cells
upon treatment with 5 mM CP, we cocultured these pretreated
cells with DCs generated from normal BM precursors. The
frequency of CD11cþMHC class IIþ DCs was elevated upon
coculture with pretreated melanoma cells, as compared with
DCs coincubated with untreated Ret cells (Supplementary
Figure S1a online). Interestingly, pretreatment of melanoma
cells with 10 mM CP failed to upregulate the major histocom-
patibility complex class II expression on DCs (Supplementary
Figure S1b online) that correlated with the failure of CP at this
concentration to induce CRT on melanoma cells (Figure 1c
and d). Furthermore, DCs cocultured with tumor cells pre-
treated with 5 mM CP displayed an increased expression of
costimulatory molecules, CD80 and CD40 (Supplementary
Figure S1b and c online). Another costimulatory molecule,
CD86, was also upregulated under similar coculture condi-
tions (data not shown).
Low-dose CP downregulates Tregs in vivo
As low doses of CP (1–2.5 mg per mouse) can decrease Treg
numbers and suppressive activity in tumor-bearing mice
(Lutsiak et al., 2005; Motoyoshi et al., 2006), we tested such
CP effect on ret transgenic mice with skin melanoma. At day 7
after the therapy onset, Treg frequencies in skin tumors were
decreased in a dose-dependent manner, as compared with
those in untreated animals (Figure 2a). A significant reduction
of Treg frequencies was also detected in the spleen of these
mice (Figure 2b). As melanoma microenvironment is
characterized by chronic inflammation, we applied a murine
model of BCG-induced chronic inflammation (Vaknin et al.,
2008) to investigate CP-mediated Treg alterations in the
absence of tumors. Similar to tumor-bearing animals, CP
injection at both the low doses significantly reduced Treg
frequencies in the peripheral blood (Figure 2c) and spleen
(Figure 2d) of inflamed mice, as compared with CP-untreated
animals.
CP therapy provides no antitumor effects and enhances chronic
inflammatory mediators
Next, we studied the effects of low-dose CP (1 or 2.5 mg per
mouse) on melanoma progression in transgenic mice. Despite
the potential induction of tumor cell immunogenicity and the
decrease in Treg frequencies, the survival of CP-treated tumor-
bearing mice was not significantly longer than that of
untreated mice (Figure 3a). Furthermore, we found no delay
in melanoma progression if low-dose CP therapy was com-
bined with the vaccination by a peptide derived from the
melanoma-associated antigen tyrosinase-related protein-2
(Figure 3a).
Next, we assessed the pattern of different chronic inflam-
matory mediators in tumor lesions. A significant increase in
concentrations of GM-CSF, IL-1b, IL-5, IL-10, IFN-g, and
tumor necrosis factor-a was found in lysates from skin tumors
and metastatic LNs of mice treated with a single CP injection
(2.5 mg per mouse), as compared with untreated tumor-
bearing animals (Figure 3b and c). Such accumulation of
inflammatory factors could support the MDSC recruitment and
activation in tumor lesions (Baniyash, 2006; Gallina et al.,
2006; Gabrilovich and Nagaraj, 2009; Ostrand-Rosenberg and
Sinha, 2009; Meyer et al., 2011).
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Figure 2. Low-dose cyclophosphamide (CP) downregulates regulatory T cells (Tregs) in tumor-bearing and inflamed mice. Mice with macroscopic tumors
or with chronic inflammation induced by Bacillus Calmette–Gue´rin (BCG) were injected intraperitoneally (i.p.) with low-dose CP (1 or 2.5mg per mouse).
At day 7, Tregs were measured by flow cytometry in (a) primary tumors and (b) spleens of tumor-bearing mice or in the (c) peripheral blood and (d) spleen
of inflamed mice. Data are shown as the percentage of CD4þCD25þFoxP3þ Tregs within total CD4þ T cells (5–10 mice per group). Three independent
experiments with similar results were conducted. Error bars represent SE. *Po0.05; **Po0.001.
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CP-induced inflammation mediates an elevation of MDSC
frequencies
Gr1þCD11bþ MDSCs were quantified in skin tumors and
spleens of transgenic mice treated with low-dose CP
(Figure 4a–c). We demonstrated a substantial accumulation
of MDSCs among leukocytes infiltrating melanomas at day 21
after the therapy with 2.5 mg CP, as compared with untreated
mice (Figure 4b). Moreover, both 1 and 2.5 mg of CP
upregulated MDSC frequencies in the spleen of tumor-bearing
mice (Figure 4c). To investigate whether the CP-induced
MDSC accumulation also occurs under tumor-independent
chronic inflammatory conditions, we treated mice exhibiting
BCG-induced chronic inflammation with a single injection of
low-dose CP (1 or 2.5 mg per mouse). Mice challenged with
BCG alone displayed an MDSC accumulation in both the
peripheral blood (Figure 4d) and spleen (Figure 4e). CP
treatment resulted in a further MDSC elevation in the
peripheral blood and in a tendency of increase in the spleen
as compared with animals injected with BCG alone (Figure 4d
and e).
Next, we tested whether CP could modulate in healthy mice
(in the absence of chronic inflammation) the frequency of
immature Gr1þCD11bþ cells, which are considered as
MDSCs in tumor-bearing animals (Gabrilovich and Nagaraj,
2009). Upon an injection of 2.5 mg CP, these cells were
expanded in the spleen, peripheral blood, and LN, but not in
BM, as compared with untreated mice (Figure 4f). No altera-
tions of cytokine or growth factor levels were detected in the
lymphoid organs of CP-treated healthy mice (data not shown).
MDSCs from CP-treated mice display an enhanced suppressive
activity
As NO and reactive oxygen species (ROS) are considered to
be among the key factors of the MDSC-induced immunosup-
pression (Serafini et al., 2006; Gabrilovich and Nagaraj, 2009;
Ostrand-Rosenberg, 2010), their production was assessed with
low-dose CP therapy in both mouse models (Figure 5). A
significant increase of NO production in tumor-infiltrating
MDSCs from mice treated with 2.5 mg per mouse was
observed as compared with untreated animals (Figure 5b).
Similar findings were obtained in mice with BCG-induced
chronic inflammation upon an injection of low-dose CP.
Levels of NO and ROS production in MDSCs from the
peripheral blood of CP-treated mice were substantially higher
than in chronically inflamed CP-untreated animals (Figure 5c
and d). However, in spleen MDSCs, although the NO and
ROS production was already significantly enhanced by the
chronic inflammation, no further elevation of both factors was
detected after the CP therapy (Figure 5e and f). In healthy
mice, immature CD11bþGr1þ cells showed no enhanced
ROS production with CP treatment (data not shown).
CP treatment aggravates chronic inflammation-induced
alterations in immune effector cells
Next, we studied whether the CP-mediated stimulation of
MDSCs could enhance their ability to suppress T-cell and
natural killer (NK) cell functions. MDSCs from tumors of
animals treated with 2.5 mg CP were cocultured with stimu-
lated syngeneic normal splenocytes. Such MDSCs suppressed
T-cell proliferation stronger than those isolated from CP-
untreated tumor-bearing mice (Figure 6a and b). Analyzing
tumor-infiltrating CD8þ T lymphocytes in CP-treated mice
(1 mg per mouse), we found a significant reduction in the
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Figure 3. Effects of low-dose cyclophosphamide (CP) therapy on melanoma
progression and chronic inflammatory factors in tumor-bearing mice. Mice
with macroscopical tumors were treated with a single intraperitoneal (i.p.)
injection of low-dose CP. (a) Survival of mice (10 animals per group) is shown
as the Kaplan–Meier curve. (b, c) Samples were taken at day 21 upon injection
of 2.5 mg CP. Levels of inflammatory mediators were detected in (b) primary
tumors and (c) metastatic lymph nodes (LNs) by Bio-Plex assay (9–16 mice per
group). Data are expressed as pg per mg protein. Three independent
experiments were conducted with similar data. Error bars represent SE. TNF-a,
tumor necrosis factor-a; TRP-2, tyrosinase-related protein-2. *Po0.05;
**Po0.01; ***Po0.001.
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frequency of these cells as compared with untreated mice
(Supplementary Figure S2a online). Moreover, we observed a
significant downregulation of intracellular perforin concentra-
tions in CD8þ tumor-infiltrating T lymphocytes isolated from
CP-treated mice (2.5 mg per mouse), suggesting their dimin-
ished cytotoxic function (Po0.05; Supplementary Figure S2b
online). A strong tendency for a decrease in perforin levels
was also detected in CD8þ T cells from metastatic LNs of
these mice (Supplementary Figure S2b online).
In the BCG-induced chronic inflammatory model, we
focused on the modulation of NK cell functions. Splenocytes
from syngeneic (C57BL/6) and allogeneic (BALB/c) mice were
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Figure 4. Low-dose cyclophosphamide (CP) mediates an enrichment of myeloid-derived suppressor cells (MDSCs) in transgenic melanoma and chronic
inflammatory models. Tumor-bearing, inflamed, and normal mice were treated with low-dose CP. MDSCs were analyzed by flow cytometry. (a) Representative
dot plots of primary tumor from untreated mice or treated with 1 or 2.5 mg CP. (b, c) Cumulative data for MDSCs in (b) primary tumors and (c) spleens from tumor-
bearing mice (8–16 mice per group) or in the (d) peripheral blood and (e) spleens from animals with chronic inflammation (4–6 mice per group) or (f) healthy mice
(4–8 mice per group) are expressed as the percentage within leukocytes. Three independent experiments were conducted with similar results. BCG, Bacillus
Calmette–Gue´rin; BM, bone marrow; LN, lymph node. Error bars represent SE. *Po0.05; **Po0.01; ***Po0.001.
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labeled with low and high carboxyfluorescein succinimidyl
ester concentrations, respectively, and administered into
C57BL/6 mice. The immunosuppression was verified by the
impaired ability of recipients to clear allogeneic cells by
cytotoxic NK cells. To test the contribution of other cells in
this effect, we depleted NK cells that resulted in almost
complete retention of allogeneic cells (data not shown). A
substantial decline of allogeneic cell clearance was detected
in the peripheral blood of chronically inflamed mice upon
treatment with low-dose CP as compared with chronically
inflamed CP-untreated mice (Figure 6c). A similar tendency of
reduced clearance was also observed in the spleen of CP-
treated mice (Supplementary Figure S3 online). Moreover,
MDSCs isolated from chronically inflamed animals treated
with 2.5 mg CP blocked proliferation of cocultured stimulated
syngeneic normal T cells (data not shown).
DISCUSSION
In this study, we highlight the complex effects of CP treatment
on the tumor and host’s immune system showing that it affects
not only tumor cells but displays diverse effects on immune
cells. Treatment of Ret melanoma cells in vitro with CP at 5
and 10 mM, which were reported to be low (Wang et al.,
2008), induced an enhanced CRT expression on AnnexinV-PI-
live cells. CRT is involved in cell adhesion, folding of new
synthesized glycoproteins, and lectin-like chaperone activity
(Obeid et al., 2007). However, in cancer cells, rapid CRT
mobilization to the cell surface at the beginning of apoptosis
(before the phosphatidylserine translocation) led to its fast
recognition by DCs through CD36-avb3,C1qR receptor
(Storkus and Falo, 2007). This phenomenon was described
as an immunogenic cell death because the phagocytosis of
such apoptotic tumor cells stimulated DCs, promoting
antitumor T-cell responses (Obeid et al., 2007). Our data on
the partial restoration of DC maturation upon their coculture
with pretreated Ret cells suggested a CP-mediated
development of immunogenic death in these tumor cells.
The administration of CP at low doses (1–2.5 mg per mouse)
(Motoyoshi et al., 2006; Sistigu et al., 2011) in vivo was found
to reduce frequencies and suppress the function of Tregs in
tumor-bearing hosts (Lutsiak et al., 2005; Motoyoshi et al.,
2006; Liu et al., 2010; Sistigu et al., 2011). The results
presented herein confirm these observations for melanoma-
bearing transgenic mice. We also demonstrated a CP-mediated
Treg downregulation in mice with chronic inflammation
induced by BCG administration, indicating that CP-mediated
reduction in Treg frequencies is tumor independent.
However, investigating the effects of low-dose CP on
melanoma progression revealed no increase of mouse survi-
val, even though immunogenic tumor cell death was induced
and Treg levels were reduced. This lack of antitumor
effects led us to suggest that CP modulated immunosuppres-
sive mechanisms in tumor-bearing mice responsible for
ineffective antitumor reactivity. One of the critical factors
inducing immune suppression and supporting tumor progres-
sion is chronic inflammation that develops in the tumor
microenvironment (Baniyash, 2006; Tan and Coussens, 2007;
Mantovani et al., 2008; Gabrilovich and Nagaraj, 2009;
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Ostrand-Rosenberg and Sinha, 2009; Ostrand-Rosenberg, 2010;
Rook and Dalgleish, 2011). Using the ret transgenic mouse
model, we have recently demonstrated an accumulation of
various chronic inflammatory factors and MDSCs in melanoma
lesions (Zhao et al., 2009; Meyer et al., 2011). In this study, we
found that low-dose CP therapy induced a significantly higher
production of several key inflammatory mediators, such as
GM-CSF, IL-1b, IL-5, IL-10, IFN-g, and tumor necrosis factor-
a, in skin tumors and metastatic LNs than in untreated tumor-
bearing animals. As all these factors are important for MDSC
expansion and activation (Baniyash, 2006; Gallina et al.,
2006; Tu et al., 2008; Gabrilovich and Nagaraj, 2009;
Greifenberg et al., 2009; Ostrand-Rosenberg and Sinha,
2009; Ostrand-Rosenberg, 2010; Stathopoulos et al., 2010;
Meyer et al., 2011) and as under CP treatment, antitumor
responses were not evident, we analyzed MDSCs as being
potential targets for the observed immunomodulation. In
CP-treated mice, a significant increase in MDSC frequencies
was observed in primary tumors, BM, and spleen, as
compared with already elevated MDSC numbers in CP-
untreated tumor-bearing mice. Increased circulating MDSC
frequencies were previously reported in breast cancer patients
and mice, with B16 melanoma injected with CP along with
doxorubicin (Diaz-Montero et al., 2009; Salem et al., 2010).
However, in contrast to our investigation, CP was used in both
studies at standard high doses. Although Liu et al. (2010)
demonstrated an expansion of tumor-infiltrating MDSCs after a
single low-dose CP injection, the modulation of MDSC
functions and chronic inflammatory microenvironment was
not addressed. We found that the MDSC enrichment in tumor-
bearing mice with low-dose CP therapy was associated with
an increased immunosuppressive activity. Moreover, such
treatment stimulated NO production that was detected
directly in these cells, which is in contrast to findings by
Loeffler et al. (2005), who measured reduced NO levels in the
serum of tumor-bearing mice after CP treatment. These
discrepancies might be because of the differences between
transplantation models and the autochthonous model used
in our study.
To characterize the role of chronic inflammation in CP-
mediated effects on MDSCs, we applied a mouse model of
BCG-induced chronic inflammation without the tumor impact
(Vaknin et al., 2008). Similar to tumor-generated conditions, a
significant increase in MDSC frequencies and enhanced ability
to produce immunosuppressive mediators (NO and ROS) with
CP administration was demonstrated. Interestingly, although a
CP-induced increase in the MDSC population was detected in
normal mice, they failed to display an enhanced NO and ROS
production. These findings suggest that chronic inflammatory
conditions developing in different pathologies could be
responsible for the enrichment and activation of MDSCs with
low-dose CP therapy. The signaling mechanisms responsible
for such CP effects are currently under investigation.
A remarkable MDSC stimulation in both mouse models
after low-dose CP treatment was found to be associated with a
marked downregulation of CD8þ T-cell and NK cell func-
tions. This could be explained by the increased MDSC
capacity to produce NO and ROS, known to induce anergy
of reactive T cells (Gabrilovich and Nagaraj, 2009;
Ostrand-Rosenberg and Sinha, 2009). Therefore, the
immunostimulatory effects of low-dose CP (e.g., a Treg
depletion and induction of immunogenic tumor cell death)
could be abrogated because of MDSC expansion and
activation in developing melanoma. This is in agreement
with a recently published report on the inability of low-dose
CP to improve immunological and clinical effects of the
multipeptide vaccination of melanoma patients (Slingluff
et al., 2011), suggesting a possible MDSC activation.
Interestingly, another study demonstrated that low-dose CP-
induced tumor-specific T-cell responses correlated with
improved clinical outcome in breast cancer patients (Ge
et al., 2011). These observations raise the question of the
predominant involvement of different immunoregulatory cells
(MDSCs or Tregs) in the progression of various tumor types
that needs further investigation.
Taken together, we found that a single injection of low-dose
CP induced an immunogenic melanoma cell death and
downregulated Treg frequencies in transgenic melanoma
mouse model. Such therapy led to a further accumulation of
chronic inflammatory mediators, inducing an enrichment and
activation of MDSCs in melanoma lesions that abrogate
potential CP antitumor effects. Similar changes were also
induced by CP in chronic inflammatory mouse model without
any tumor impact. CP-induced enhancement of immunosup-
pression resulted in the impairment of innate and adaptive
immunity as reflected by the downregulation of CD8þ T-cell
and NK cell functions. We suggest that tumor immunotherapy
with low-dose CP should include neutralization of chronic
inflammatory factors and block MDSC immunosuppressive
functions, which are enhanced with CP treatment.
MATERIALS AND METHODS
Mice
Ret transgenic mice provided by Dr I Nakashima (Chubu University,
Aichi, Japan) were kept in the specific pathogen-free facility of
German Cancer Research Center (Heidelberg, Germany) Experiments
were conducted on female and male tumor-bearing mice that were
6–7 weeks of age. Female C57BL/6 mice, 7–8 weeks of age, were
purchased from Harlan (Jerusalem, Israel) and kept at the Hebrew
University specific pathogen-free facility (Jerusalem, Israel). Animal
experiments were conducted in accordance to the government and
institutional guidelines and regulations.
Reagents and antibodies
Medium RPMI-1-640 was purchased from PAA (Coelbe, Germany).
CP was from Sigma (Munich, Germany). Diaminofluoresciein-2
diacetate and aminophenyl fluorescein were from Cell Technology
(Mountain View, CA). Rat anti-mouse directly conjugated mAbs
(CD3-PerCP-Cy5.5, CD4-FITC, CD8-APC-Cy7, CD25-APC, CD45.2-
PerCP-Cy5.5, CD11b-PE, Gr1-PE-Cy7, I-Ab-FITC, CD40-PE, CD80-
PE, CD86-PE, and CD11c-APC) were from BD Biosciences (Heidel-
berg, Germany). FoxP3 fixation/permeabilization kit, rat anti-mouse
Foxp3-PE mAbs, and AnnexinV/PI apoptosis staining kit were from
eBioscience (San Diego, CA). Purified rabbit anti-mouse CRT (Santa
Cruz, Heidelberg, Germany) and goat anti-rabbit IgG-AlexaFluor 488
(Invitrogen, Karlsruhe, Germany) were also used.
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Mouse model of chronic inflammation
BCG (Difco Laboratories, Detroit, MI) was administrated into C57BL/
6 mice, as previously described (Vaknin et al., 2008).
CP treatment in vitro and in vivo
Ret cells established from skin melanoma of transgenic mice were
incubated with 5 or 10 mM of CP for 24 hours. DCs were generated
from the BM of normal mice as described (Shurin et al, 2009). Before
co-incubation with DCs, CP-treated Ret cells were washed twice.
Transgenic tumor-bearing mice received a single intraperitoneal
injection of CP (1 or 2.5 mg per mouse). Mice with BCG-induced
chronic inflammation were injected intraperitoneally with 1 or 2.5 mg
CP 2 days after the second BCG injection. Control groups consisting
of tumor-bearing transgenic mice or BCG-treated animals received
phosphate-buffered saline.
Immunization
Tumor-bearing transgenic mice were immunized with the tyrosinase-
related protein-2–derived peptide (SVYDFFVWL), as described (Firat
et al, 1999), simultaneously with the CP administration.
Flow cytometry
Single-cell suspensions prepared from the tumor, spleen, LN, and BM
were treated with Fc-block and mAbs for 30 minutes at 4 1C.
Acquisition was performed by multicolor flow cytometry using
FACSCanto II with FACSDiva software (both from BD Biosciences)
with dead cell exclusion. FlowJo software (Tree Star, Ashland, OR)
was used to analyze at least 100,000 events.
Bio-Plex assay
Snap-frozen tumor and LN samples were disrupted and treated with
lysis solution (Bio-Rad, Munich, Germany). Concentrations of inflam-
matory factors were measured by multiplex technology (Bio-Rad)
according to the manufacturer’s protocol.
In vitro proliferation assay
CD11bþ cells were isolated from tumors of transgenic mice using
CD11bþ MicroBeads isolation kit (Miltenyi Biotec, Bergisch Glad-
bach, Germany) according to the manufacturer’s protocol. The
proportion of Gr1þCD11bþ MDSCs in selected population was
B80%. C57BL/6 splenocytes were labeled with carboxyfluorescein
succinimidyl ester (Invitrogen; final concentration of 2.5mM), stimu-
lated with anti-CD3 and anti-CD28 mAbs (0.5mg ml 1 each), and
cocultured with MDSCs in a ratio of 1:1 for 96 hours. T-cell
proliferation was evaluated using flow cytometry.
In vivo cytotoxicity assay
Specific clearance of carboxyfluorescein succinimidyl ester–labeled
allogeneic splenocytes in C57BL/6 mice was performed and evalu-
ated as described before (Vaknin et al., 2008).
Statistical analysis
Results were assessed with Student’s t-test and Mann–Whitney U-test
using GraphPad Prism software (San Diego, CA). Differences in
values at Po0.05 were considered significant.
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